Market Overview

UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Related NBIX
Benzinga's Volume Movers
Morning Market Gainers

Morgan Stanley initiated its coverage on Neurocrine Biosciences (NASDAQ: NBIX) with an Overweight rating and a $12 price target.

Morgan Stanley said, "Neurocrine has a differentiated lead asset, elagolix, targeting large markets with segments of unmet need. We believe the Street undervalues this asset. We expect elagolix success in endometriosis and uterine fibroids (UF) and model combined WW sales of ~$720mn in 2020."

Neurocrine Biosciences closed at $8.30 on Wednesday.

Latest Ratings for NBIX

Jul 2015Leerink SwannAssumesOutperform
Jun 2015Piper JaffrayMaintainsOverweight
Mar 2015JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (NBIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters